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protein-coupled receptors (GPCRs; LPAR1-6), which exhibit overlapping specificities and widespread distribution. (3) Up-regulated ATX expression has been detected in various chronic inflammatory disorders and different types of cancer. (4, 5) ATX was shown to play a decisive role in the development of pulmonary fibrosis (6) ; however, little is known about its role and mode of action in other fibroproliferative diseases.
Expanding and complementing previous studies, (7) we have shown increased serum ATX levels in CLDs of different etiologies, correlating with decreased survival, as well as increased liver ATX mRNA expression, in both CLD and HCC patients. Accordingly, increased hepatocyte ATX and liver LPA levels were shown in animal models of experimental toxic hepatitis and HCC. Genetic and pharmacological interventions in vivo, coupled with ex vivo studies, indicated that ATX disturbs lipid homeostasis and promotes the development of both fibrosis and cancer.
Materials and Methods

HUMAN SUBJECTS
Clinical and personal characteristics of patients are presented in Supporting Table S2 . Clinical investigations have been conducted according to Declaration of Helsinki principles. All patients and controls consented for anonymous research usage of their samples, as approved by the Ethical Committee of the University of Thessaly Medical School.
ANIMAL EXPERIMENTATION
All experimental mice were bred and maintained in a C57Bl6/J genetic background (>10 generations) under specific pathogen free conditions at [20] [21] [22] o C, 55 6 5% humidity, and a 12-hour light-dark cycle; water and food (irradiated standard diet Mucedola #4RF21) were provided ad libitum. Generation and genotyping protocols for Enpp2 n/n , (8) TgAlb-Cre, (9) R26R, (10) and Tga1t1-hEnpp2 (11) mice have been described. All randomly assigned experimental controls were littermate sex-and age-matched mice. All reported experimentation in mice for this project, in line with the ARRIVE guidelines, was approved by the Institutional Animal Ethical Committee (#377) and the Veterinary service and Fishery Department of the local governmental prefecture (#5366).
Acute and chronic intoxication with diethylnitrosamine (DEN) and/or CCl 4 , liver histology, liver cell isolation and hepatitis C virus (HCV) infection, highperformance liquid chromatography (HPLC)/electrospray ionization (ESI) tandem mass spectrometry (MS/MS), ATX activity assay (TOOS), enzymelinked immunosorbent assay (ELISA), western blotting, RNA extraction and real-time RT-PCR are described in the Supporting Information.
STATISTICAL ANALYSIS
Statistical analysis is indicated accordingly in the individual figure legends.
Results
INCREASED ATX EXPRESSION IN CLD PATIENTS OF DIFFERENT ETIOLOGIES
To interrogate human patients liver mRNA expression of ATX, as well as of LPA receptors (LPAR1-6) and phospholipid phosphatases (PPAP2A-C/LPP1-3),
ARTICLE INFORMATION:
we performed data mining in all CLD patient microarray data sets publically available at NCBI/GEO (Supporting Table S1A ). Statistically significant increased ATX mRNA expression was found in the majority of data sets/patient cohorts; the same is true for LPAR6, previously suggested to support the tumorigenicity of HCC. (12) Similarly, increased ATX mRNA levels were also detected in HCC data sets (Supporting Table S1B ), accompanied by decreased expression of PPA2PB suggested to mediate LPA turnover. (13) Increased ATX sera levels were identified in patients with CVH (including HCV and hepatitis B virus), as well as in ALD and NASH patients ( Fig. 1A ; Supporting Table S2 ), suggesting ATX as a biomarker in all CLDs regardless of the initiating insult. Noteworthy, the CVH patient group, exhibiting a large number of values close to the normal range, included 18 samples from patients with inactive disease as a result of the appropriate antiviral treatment. Interestingly, ATX levels in responding patients were significantly lower (155 ng/ mL; P 5 0.04) than 17 treatment-na€ ıve CVH patients with an active disease (as defined by biochemical activity and/or viral replication; 285 [109-3,500] ng/mL).
Significant, albeit weak, associations of serum ATX levels were also discovered with a number of surrogate disease parameters (Supporting Table S3 ), including aspartate aminotransferase/alanine aminotransferase (ALT) and bilirubin, indicative of hepatic damage and loss of function, respectively. Importantly, low serum ATX levels were significantly associated with longer overall survival in a 10-year follow-up period (Fig. 1B) , further suggesting ATX as a prognostic indicator of disease severity.
INCREASED, WELL-TIMED LIVER ATX EXPRESSION IN EXPERIMENTAL TOXIC HEPATITIS
Chronic exposure to CCl 4 resulted, as expected, in focal, confluent, and portal necrosis, followed by portal inflammatory infiltration (Supporting Fig. S1A disease development ( Supporting Fig. S2F) ; however, significant aSMA protein expression was first detected at 4 weeks (Fig. 2C) , the peak of ATX expression, accompanied by a major shift in the C-X-C chemokine receptor (Cxcr)4/Cxcr7 mRNA expression ratio (Supporting Fig. S2G ), increased cytochrome P450 2S1 (Cyp2S1) mRNA levels (Supporting Fig. S2G ) and increased plasma levels of retinoic acids (RAs; Supporting Fig. S2H ). Therefore, CCl 4 -induced, ATX well-timed liver expression coincided with the expression of several markers of HSC activation, suggesting a role for ATX in the modulation of HSC physiology and establishment of fibrosis.
DISORDERED PHOSPHOLIPID HOMEOSTASIS IN EXPERIMENTAL TOXIC HEPATITIS
To possibly correlate ATX levels with the levels of its enzymatic product, LPA, as well as to detect other possible disturbances in lipid homeostasis, we next performed lipidomic analysis of CCl 4 -induced disease progression with HPLC-MS/MS. Clustering of lipid expression levels identified four major groups of lipids with deregulated expression (Fig. 2E) .
The first group was composed mainly of LPA species, exhibiting comparatively the highest upregulation in liver tissue, peaking at 4 weeks both in liver tissue and plasma ( Fig. 2E and Supporting Fig.  S4A ,B). As in human CLD patients (Supporting Table S1A ), Lpar6 exhibited the highest expression in the liver, peaking at 4 weeks (Supporting Fig. S2I ). Therefore, the increased liver ATX expression upon damage led to local increases of LPA, possibly further sustained by the identified decrease in Ppap2b levels (Supporting Fig. S2J) .
A second group of lipids was composed mainly of LPC species peaking at 4 weeks ( Fig. 2E and Supporting Fig. S4E,F) . Accordingly, most liver-abundant phospholipase A2 (Pla2) isoforms, largely responsible for liver LPC synthesis, were found up-regulated at 2-4 weeks post-CCl 4 administration (Supporting Fig.  S2K ). In agreement, expression profiling of all publicly available human CLD data sets, as described above, indicated a liver overexpression of PLA2 g4C, g5, and g7 isoforms (Supporting Table S1C ), suggesting a parallel involvement of the PLA2/LPC axis in the pathogenesis of CLDs and toxin-induced hepatitis.
The third group (Fig. 2E ) was composed mainly from triacylglycerols (TAGs), in agreement with the observed neutral lipid deposition (Supporting Fig.  S1O -Q). The last group, a clustering node by itself, was composed mainly of phosphatidyl ethanolamine (PE) and lysoPE species that surged in the plasma, most likely as a direct toxic effect of CCl 4 on cell membranes.
HEPATOCYTE INJURY OR INFECTION STIMULATES ATX EXPRESSION
The increased ATX expression in the liver was localized mainly to Heps by double immunolabeling, which, furthermore, indicated that aSMA-expressing myofibroblasts are not major producers of ATX (Fig.  3A) . Accordingly, fractionated primary Heps were found to produce and secrete the vast majority of ATX (Fig. 3B,C) , further confirming the increased Hep ATX expression upon CCl 4 intoxication (Fig. 3D) .
ATX expression from Heps (and Kupffer cells [KCs]) ex vivo was stimulated by TNF and lipopolysaccharide (LPS; Fig. 3E ,F), whereas elevated liver ATX levels were detected upon concanavalin A (ConA)-induced, T-cell-dependent, and TNFmediated, inflammatory Heps damage in vivo (Supporting Fig. S5 ). (14) Remarkably, ATX expression was also stimulated upon HCV (Japanese fulminant hepatitis type 1; JFH-1) infection in the permissive Huh7.5 hepatoma cell line or pJFH-1 RNA transfection in Hep2G cells (Supporting Fig. S6A,B) .
Remarkably, LPC (18:1) was also shown to be a potent stimulus of ATX expression from Heps ex vivo -/-mice. Fold changes to the respective littermate oil-treated control values are shown; clustering was performed using the Euclidean's distance metrics. All values in all panels are mean 6 SEM; n 5 4-6. *P < 0.05; analysis of variance post-hoc test. Scale bars: 150 lm. Abbreviations: Ctrl, control; hyb., hybridization; IHC, immunohistochemistry; w, weeks; WT, wild type.
(Supporting Fig. S6C,D) , while promoting their apoptosis (Supporting Fig. S6E,F) . In agreement, LPC administration (18:1; 60 mg/kg intravenously) in mice in vivo led to an increase of both ATX and apoptosis (Supporting Fig. S6G-J) , suggesting LPC as a potent ATX inducer in the liver. On the contrary, no major LPA effect in hepatocyte ATX expression was observed (Fig. 3E) . (15) 
HEPATOCYTE-SPECIFIC ATX EXPRESSION ACTIVATES HEPATIC STELLATE CELLS AND AMPLIFIES THE FIBROTIC RESPONSE
To examine whether Hep-specific ATX expression plays a pathogenic role in the development of liver fibrosis, ATX was genetically deleted from Heps by mating the conditional knockout mouse for ATX (Enpp2 n/n ) (8) with a transgenic mouse line expressing the Cre recombinase under the tight control of the albumin (Alb) promoter (TgAlb-Cre), directing efficient recombination of floxed alleles specifically to Heps (Supporting Fig. S7A,B) . (9, 10) Accordingly, no Hep ATX expression could be detected in AlbEnpp2 -/-mice 4 weeks post-CCl 4 administration (Fig. 4Aa,B) , followed by diminished liver and plasma LPA levels ( Fig. 4C and Supporting Fig. S7C,D) and a complete reversal of the corresponding lipidomic profiles (Fig.  2E) , thus suggesting that CCl 4 -induced Heps-specific ATX expression results in local LPA production, that is also reflected in the circulation.
Abrogation of liver ATX/LPA production resulted in diminished necrosis (Fig. 4Ab,D) , apoptosis (Supporting Fig. S7Ea and Fig. 4D ), and proliferation (Supporting Fig. S7Eb and Fig. 4D) ; however, the number of hydropic cells increased in the absence of ATX (Fig. 4Ab,D) , suggesting that ATX/LPA might interfere with ionic and/or fluid homeostasis. (16) The overall liver inflammatory histopathological score was not significantly reduced (Fig. 4D) , although parenchymal inflammation appeared more diffuse rather than periportal (Fig. 4Ab) , inflammatory gene expression was modulated (Supporting Fig. S7F) , and a reduction in the number of infiltrating Gr1 1 cells and activated macrophages was observed (Supporting Fig.  S7I ). Moreover, ATX deletion diminished the deposition of neutral lipids, but had no effect on glycogen deposition (Supporting Fig. S7E ). More important, ATX ablation led to a diminished histopathological fibrotic score (Fig. 4D) , consistent with decreased collagen production (Fig. 4E) , profibrotic gene expression (Fig. 4F ), aSMA expression (Fig. 4Ad) , as well as liver damage (Supporting Fig. S7G,H) .
Conversely, CCl 4 administration to Tga1t1-hEnpp2 mice, overexpressing a human ATX transgene in Heps driven by the human a1-antitrypsin inhibitor (a1t1) promoter, (11) resulted in increased collagen deposition and fibrosis (Supporting Fig. S8 ). ATX/LPA levels in CCl 4 -treated Tga1t1-hEnpp2 mice were not significantly higher than CCl 4 -treated wild-type littermates (Supporting Fig. S8G-I) , given that transgenic a1t1-driven hATX expression was not CCl 4 induced (Supporting Fig. S8J ), suggesting that the chronic exposure to LPA, rather than its absolute levels, exerted the observed profibrotic effect.
In agreement with a chronic role of ATX/LPA pathogenetic effects in liver injury, ATX Heps ablation or overexpression led to minimal changes in the ConA Genetic deletion of ATX from hepatocytes also had minor effects in liver regeneration following partial hepatectomy (Supporting Fig. S10A,B) , suggesting no major effects of ATX/LPA in hepatocyte proliferation, as observed in vitro (Supporting Fig. S10C,D) . LPA stimulated Tnf, Il-6, and Cxcr4 expression in primary hepatocytes in vitro ( Supporting Fig. S10C) ; however, the relative contribution of LPA-induced hepatocyte responses to the overall liver proinflammatory and profibrotic gene expression (Supporting Fig. S2E-G) remains unknown.
Despite the minimum involvement of ATX in acute liver damage, deletion, or overexpression of ATX, in AlbEnpp2 -/-or Tga1t1-hEnpp2 mice, respectively, modulated accordingly Acta2/aSMA liver mRNA levels 24 hours postacute exposure to CCl 4 (Fig. 5A,B) , further supporting a decisive role of ATX/LPA in hepatic stellate cell (HSC) activation. In agreement, LPA stimulation of serum-starved primary HSCs in vitro stimulated aSMA expression (Fig. 5C) , while promoting the rearrangement of their actin cytoskeleton, and inhibiting their serum-starvation-induced apoptosis (Fig. 5D,E, respectively) .
PHARMACOLOGICAL INHIBITION OF ATX ATTENUATES CCl 4 -INDUCED FIBROSIS
To translate the genetic findings into potential treatment options, CCl 4 -treated mice were administered (2-4 weeks post-CCl 4 ) with 30 mg/kg (intraperitoneally, twice-daily) of PF8380, a potent (half maximal inhibitory concentration, 1.9 nM) and well-characterized (17, 18) ATX inhibitor. Pharmacological ATX inhibition attenuated CCl 4 -induced fibrosis (Fig. 6A-F) , confirming the genetic results and suggesting ATX as a potential therapeutic target in liver fibrosis.
HEPATOCYTE-SPECIFIC ATX GENETIC DELETION ATTENUATES HCC DEVELOPMENT
To examine a possible role of ATX/LPA profibrotic effects in HCC development, male AlbEnpp2 -/-mice were administered, before CCl 4 intoxication and the observed effects in liver pathophysiology and ATX expression, with DEN (50 mg/kg; intraperitoneally at 15 days postpartum), thus coupling a genotoxic mutagenic insult with toxin-induced fibrosis that results in HCC. (19) All DEN/CCl 4 -treated, surviving (60%; Fig. 7A ) control mice developed HCC (Fig. 7B) . Among them, the majority (70%) developed tumors in all the liver lobes; in the remaining mice, tumorigenesis was confined to the caudate lobes and left lateral lobes (Supporting Fig. S11A ). Increased ATX mRNA levels were detected upon HCC development (Fig. 7C) ; no changes in ATX plasma activity were observed (Supporting Fig. S11B ). ATX staining localized in tumor cells, missing from healthy surrounding Heps (Supporting Fig. S11C ).
ATX genetic deletion attenuated ATX mRNA and plasma activity levels ( Fig. 7C and Supporting Fig.  S11B, respectively) ; however, residual ATX staining in remaining tumors could still be detected (Supporting Fig. S11C ), most likely as a result of not complete (<100%) recombination and/or possible ATX attachment to membrane receptors, such as integrins. (20, 21) All (100%) DEN/CCl 4 -treated AlbEnpp2 -/-mice survived the treatment (Fig. 7A) ; among them, 30% did not develop any tumors and 45% developed tumors only in some liver lobes (caudate lobes and left lateral lobe; Fig. 7B and Supporting Fig. S11A ), suggesting that ATX/LPA amplify oncogenic signals. The dramatic reduction of both tumor number and size (Fig. 7D,E) was also reflected in liver weight (Supporting Fig. S11D ). Histological analysis indicated a reduction trend in necrosis, inflammation, and fibrosis (Supporting Fig. S12A-D) and a significant decrease in CD34 and PCNA staining (Supporting Fig. S12E-H) ; however, the most prominent histological feature observed upon the genetic deletion of ATX was a significant decrease of neutral lipid deposition (Fig. 7F) . 
ATX DISTORTS HCC-RELATED FATTY ACID METABOLISM
Lipidomic analysis indicated up-regulated levels of liver LPA upon HCC development, found to be diminished upon the genetic deletion of ATX ( Fig. 2E and Supporting Fig. S11F ). Noteworthy, Ppap2b mRNA levels were found to be decreased also in HCC (Supporting Fig. S11G ), as shown (Supporting Table  S1B ) for human HCC patients, possibly accounting for the sustainment of LPA levels. Although PPAP2s have been also incriminated for sphingosine-1-phosphate (S1P) degradation, (22) no major differences in S1P levels were observed in HCC ( Supporting Fig.  S11H) ; however, large increases in expression of sphingosine-1-phosphate receptor 3 were observed upon HCC development, found to be diminished after ablation of ATX and LPA (Supporting Fig. S11K ; Supporting Table S5 ), in agreement with previous in vitro studies. (23) Strikingly, liver accumulation of some TAG species in DEN/CCl 4 -induced HCC was the most prominent feature of the HCC lipidomic profile (Fig. 2E) ; HCC TAG levels were found reduced in the absence of ATX, in agreement with the observed decreased neutral lipid deposition, suggesting a novel role for ATX/ LPA in HCC-related fatty acid (FA) metabolism.
To obtain mechanistic insights into the mode of action of the ATX/LPA axis in HCC development, we performed whole-liver, genome-wide expression profiling of DEN/CCl 4 -induced HCC. Stringent gene set enrichment analysis of statistical significant differentially expressed genes (DEGs) upon HCC development in the absence of ATX identified mostly genes involved in lipid metabolism, as well as genes coding for plasma membrane and actin binding proteins (Supporting Table S4 ). Expression of a large number of ATX/ LPA-affected genes seem to be regulated by the transcription factor, activator protein 1 (AP-1) (Supporting Table S4 ), a critical transcriptional regulator of invasion (24) reported to be regulated by LPA.
Comparison of HCC DATX and HCC DEGs revealed genes that are up-regulated in the liver upon HCC development, but reverted toward physiological levels in the absence of ATX (Supporting Table S5 ). The HCC-induced, possibly ATX/LPA-regulated genes (ATX-rDEGs; Supporting Table S5 ) include alpha-fetoprotein (Afp) and glypican 3 (Gpc3), established HCC serum markers, (25) as well as wellknown markers of oncofetal transformation (Afp, H19, and brain expressed X-linked 1), (19, 26) proving, on a molecular level, that ATX deletion attenuates HCC.
Among the multiple ATX-rDEGs involved in lipid metabolism, stearoyl-CoA desaturase 2 (Scd2) was previously shown to be necessary for the biosynthesis of monounsaturated FA, essential components of TAGs. (27) DEN/CCl 4 -mediated HCC development induced its expression, whereas ATX deletion attenuated its mRNA levels (Supporting Table S5 ; confirmed with Q-RT-PCR, Fig. 8A ). In agreement, LPA stimulation of HepG2 cells in vitro stimulated SCD mRNA expression (Fig. 8B) , neutral lipid deposition (Fig. 8C,D) , and cellular TAG levels (as determined with liquid chromatography/MS; Fig. 8E ).
Discussion
Increased ATX sera levels were detected in CLD patients of different etiologies, associated with shorter overall survival and surrogate disease parameters indicative of hepatic damage and loss of function (Supporting Table S3 ). (28) Moreover, increased liver ATX mRNA expression was found in the majority of publically available CLD and HCC microarray data sets, thus suggesting that hepatocyte injury can stimulate autologous ATX expression and that ATX, beyond its diagnostic or prognostic value, might also play a direct role in liver pathophysiology.
In agreement, robust ATX and LPA expression was detected in CCl 4 -intoxicated injured mouse livers. ATX expression was localized mainly to hepatocytes, found to be induced by HCV infection, TNFmediated inflammation, as well as exposure to LPC, all pathological stimuli linked with the development of different forms of human CLDs. Interestingly, TNF has been reported to stimulate ATX expression in hepatoma cells in vitro through nuclear factor kappa B (NF-jB), (29) whereas LPS, a well-known activator of NF-kB in macrophage-like cells, (30) has also been shown to induce ATX expression in monocytic THP-1 cells, (31) as shown here with primary KCs. LPC has been also shown to activate NF-kB in keratinocytes and pancreatic AR42J cells, (32, 33) whereas the activation of NF-kB is well established in HCV infections. (30) Moreover, in silico analysis of the Ennp2 promoter revealed NF-kB target sites, validated by the respective coimmunoprecipitations, (34) strongly suggesting that ATX expression in the inflamed liver is controlled, at least in part, by NF-kB, which had been suggested to link injury, fibrosis, and HCC, depending on cellular context and timing, as well as on activation thresholds. (30) Hepatocyte ATX expression and LPA production in CCl 4 -intoxicated mouse livers coincided with a proliferative peak of hepatocytes, although no major effect of ATX/LPA in hepatocyte proliferation was observed in vitro, or in hepatectomized mice in vivo. Moreover, hepatocyte-specific ATX deletion and the consequent reduction in local LPA levels attenuated neutral lipid deposition. In agreement and as recently presented, (35) hepatocyte-specific ATX deletion abrogated lipid deposition in the liver and the development of steatosis in a more relevant, high-fat-diet-induced NASH metabolic model, associated with reduced expression of major lipogenic genes. However, the relative contribution of ATX/LPA to FA synthesis and TAG deposition in comparison with other converging pathways, as well as exogenous FA sources, remains to be determined.
On the other hand and most importantly, ATX expression also coincided with up-regulated aSMA protein expression, Cyp2S1 mRNA expression, and RA levels; all established markers of HSC activation. (36) Deletion or overexpression of ATX from hepatocytes accordingly modulated aSMA levels in all disease models examined, whereas exposure of primary HSCs to LPA promoted cytoskeletal rearrangements, inhibited apoptosis, and stimulated aSMA expression. Moreover, ATX well-timed expression coincided with the transition from regeneration to fibrosis, as shown with a major shift in the expression ratio of Cxcr4/Cxcr7, a recently reported modeled disease hallmark. (37) This predominance of CXCR4 over CXCR7 is thought to shift the angiocrine response of liver sinusoidal endothelial cells, which it has been recently shown can be modulated by LPA, (38) stimulating proliferation of HSCs and enforcing a profibrotic vascular niche. (37) Therefore, CCl 4 -induced and LPC-driven, hepatocyte ATX expression enforces the entry to the perpetuation phase of fibrosis development by activating HSCs, directly or indirectly, through LPA, whose levels are possibly sustained in relatively high levels attributable to the downregulation of Ppap2b expression, further stimulating collagen production and hepatic fibrosis.
LPC, the main enzymatic substrate of ATX and a potent inducer of its Hep expression, peaked at 4 weeks post-CCl 4 in liver tissue, as also suggested for NAFLD patients. (39) Moreover, LPC administration has been reported to promote hepatitis (39) ; interestingly, rats fed a high-fat diet displayed elevated serum ALT levels that correlated with increased Pla2 mRNA expression and LPC levels, (40) suggesting that LPC and ATX/LPA could mediate diet and/or obesity effects in liver pathophysiology, as suggested for prostate disease. (41) Different PLA2 isoforms were detected aberrantly expressed in mouse and human fibrotic livers, further supporting liver-specific de novo LPC synthesis upon damage, and suggesting a synergy of the PLA2/LPC and LPA/ATX axes in hepatitis development. (42) Conditional genetic deletion of ATX from Heps and abrogation of liver production of LPA modulated inflammation and diminished fibrosis, thus establishing ATX as a liver profibrotic factor. Conversely, transgenic Heps-ATX overexpression promoted collagen deposition and fibrosis; noteworthy, transgenic liver ATX expression did not induce any liver phenotype per se, suggesting that ATX expression is not sufficient to induce fibrosis, but is rather required to amplify profibrotic signals.
Deletion of ATX from Heps and down-regulation of liver LPA levels had also a profound effect in DEN/ CCl 4 -induced HCC, promoting mice survival and attenuating both liver tumor numbers and size. In agreement with a procarcinogenic role for ATX, transgenic overexpression of ATX in the mammary gland resulted in spontaneous breast cancer in aged mice (43) ; noteworthy, the late onset suggests that ATX is not sufficient to promote carcinogenesis per se, as shown here for fibrosis, but is rather required to amplify oncogenic age-related signals. Moreover, reported LPA effects in vitro are concordant with several of the suggested hallmarks of cancer, a conceptual framework of essential alterations in cell physiology that collectively dictate malignant growth in most tumors. (44) LPA effects, mediated by pathways well consistent with their identity as GPCRs, include proliferation, resistance to cell death, angiogenesis, as well as invasion and metastasis. (5) Cancer cells, under the pressure of increased proliferation and growth, have been suggested to reprogram their cellular energy metabolism in many different ways, including an increase in glutamine metabolism, the decoupling of glycolysis from pyruvate oxidation in mitochondria (the Warburg effect), and de novo FA synthesis, despite sufficient dietary supply and/or increased lipolysis in adipose tissue. (44, 45) Excessive FAs, that can be detrimental for the cell, are esterified with glycerol backbones generating TAGs that are stored in lipid droplets. (44, 45) At times of metabolic need, such as malignant growth, accumulated TAGs can be converted back to FAs through emerging lipolytic mechanisms that were also reported to be upregulated in cancer. (44, 45) Although this delicate balance of FA metabolism in cancer is far from being understood, FAs are essential to cancer cells for the synthesis of structural lipids required for the generation of new cells and the required energy production to sustain it, the biosynthesis of protumorigenic signaling lipids, as well as the resistance to oxidative-stressinduced cell death and chemotherapy. (44, 45) Strikingly, the most prominent histopathological effect of ATX deletion in DEN/CCl 4 -induced HCC was the significant decrease of neutral lipid deposition, indicating perturbations in FA metabolism; no significant liver accumulation of TAGs was detected upon the genetic deletion of ATX, whereas expression profiling revealed, as mostly affected, genes that are involved in lipid metabolism. Among them, Scd2 expression, essential for FA synthesis during early liver development, (27) was shown to be aberrantly reactivated in DEN/CCl 4 -induced HCC, and was found to be stimulated by LPA in vitro, correlating with increased TAG accumulation. In support, Scd2 expression has been shown to be regulated by sterol regulatory element-binding proteins (SREBPs; SREBP1a and 2), (46) transcription factors regulating FA synthesis, (46) and shown to be stimulated by LPA. (47) Pharmacological inhibition of SCD, as well as of other enzymes involved in FA synthesis, have been reported to reduce tumor growth and are currently at different levels of preclinical and clinical development. (45) Noteworthy, ATX/LPA also stimulated the expression of a large number of lipase genes (Supporting Tables S4 and  S5) , such as Patatin-like phospholipase domaincontaining 5 (Supporting Table S5 ), a neutral lipase that localizes to lipid droplets and has been shown as a link of TAG mobilization and autophagy. (48) Therefore, the ATX/LPA axis is critically involved in FA metabolism in cancer cells, in concert with other lipidmodifying enzymatic cascades and likely orchestrated from the adipose tissue, thus contributing to the reprogramming of energy metabolism in malignant cells, an emerging and maybe central cancer hallmark.
Pharmacological inhibition of ATX with PF8380 attenuated CCl 4 -induced fibrosis, in agreement with the genetic deletion results. Noteworthy, ATX was recently reported to be inhibited by selective binding of the bile salt, taurourdeoxycholate (TUDCA), (49) an established treatment of primary biliary cirrhosis and other cholestatic disorders, suggesting that TUDCA efficacy could be partly attributed to ATX inhibition. Therefore, ATX emerges as a potential therapeutic target in CLDs and possibly HCC, perhaps as an adjuvant therapy to current treatment options.
